Vicebio Ltd cashes in US$100m in Series B financing

Vicebio Ltd’s US$100m financing was led by new investor TCGX, alongside Goldman Sachs Alternatives, Avoro Ventures, venBio, and with participation from UniQuest and founding investor Medicxi. According to the British vaccine maker, the proceeds will be used to support two pipeline products: Firstly, advancing Phase I testing of its candidate VXB-241 that targets both, the Respiratory Syncytial Virus (RSV) and the Human Metapneumovirus (hMPV), and second, VXB-251, a trivalent vaccine targeting RSV, hMPV and Parainfluenza Virus 3 (PIV3). Initial readouts from the Phase I study of VXB-241 are expected mid 2025.

Vicebio’s Molecular Clamp platform, co-developed by Keith Chappell at The University of Queensland, stabilises viral glycoproteins in their immunogenic prefusion conformation. According to the company, its platform technology is applicable to a wide range of viruses including Respiratory Syncytial Virus (RSV), Human Metapneumovirus (hMPV), Parainfluenza virus, Influenza and Coronaviruses, as confirmed by preclinical and clinical studies.

In connection with the financing, the Vicebio Board of Directors will expand to include Cariad Chester, Managing Partner at TCGX, Colin Walsh, Managing Director at Goldman Sachs and Mark Chin, Partner at Avoro Ventures.